The DrugBank database is a unique bioinformatics and cheminformatics resource that combines detailed drug data with comprehensive drug target information.

The latest release of DrugBank (version 5.1.5, released 2020-01-03) contains 13,533 drug entries including 2,629 approved small molecule drugs, 1,372 approved biologics (proteins, peptides, vaccines, and allergenics), 131 nutraceuticals and over 6,355 experimental (discovery-phase) drugs. Additionally, 5,211 non-redundant protein (i.e. drug target/enzyme/transporter/carrier) sequences are linked to these drug entries. Each entry contains more than 200 data fields with half of the information being devoted to drug/chemical data and the other half devoted to drug target or protein data.

About DrugBank
Cite DrugBank
DrugBank for Commercial Use
DrugBank top drugs
  1. Morphine
  2. Oxycodone
  3. Acetaminophen
  4. Codeine
  5. Salbutamol
  6. Acetylsalicylic acid
Featured Article
Read Full Article
COVID-19: Finding the Right Fit

Identifying Potential Treatments Using a Data-Driven Approach

Download the White Paper
Featured Drug
Db14761

Remdesivir

Remdesivir, or GS-5734, is an adenosine triphosphate analog first described in the literature in 2016 as a potential treatment for Ebola. In 2017, its activity against the coronavirus family of viruses was also demonstrated. Remdesivir is also being researched as a potential treatment to SARS-CoV2, the coronavirus responsible for COVID-19.

DrugBank is offered to the public as a freely available resource.

Use and re-distribution of the data, in whole or in part, for commercial purposes (including internal use) requires a license. We ask that users who download significant portions of the database cite the DrugBank paper in any resulting publications.

Cite DrugBank
DrugBank for Commercial Use